A Randomized, Open-label, Three-arm Study of MZRW on Tolerability,

Status Completed

Clinical Trial Summary

This is a randomized open-label, three-arm, phase 1 clinical study. The investigators aim to investigate a Chinese Proprietary Medicine, MZRW on its tolerability, system exposure and pharmacokinetics profile.

Clinical Trial Description

This is a randomized, open-label, three-arm study. The participants will be enrolled and randomized in a ratio of 1:1:1 to receive 5.0g, 7.5g, 10g b.i.d. of MZRW at 9 am respectively. The study drug, MZRW will be administrated to the participants by site personnel after participants have fasted overnight for more than 8 hours and 6 hours after administration. Each participant will consume a standardized meal. In addition, the participants refrain from Semen Cannabis Sativae, Semen Pruni Armeniacae, Radix Paeoniae, Fructus Immaturus Citri Aurantii, Cortex Magnoliae and Radix et Rhizoma Rhei foods for 3 days before the study until completion of the study.

Blood samples (5 ml each) will be collected from the medial cubital vein into evacuated tubes containing heparin just before and at 0.25, 0.5, 1, 2, 4, 8, 12h after administration and were immediately centrifuged (1700g, 10 min). Plasma fractions were stored at -20°C until analysis. All study procedures conduct in accordance with the ethical principles of the Declaration of Helsinki, consistent with Good Clinical Practice guidelines, and approved by Hong Kong Baptist University Ethics Committee on the Use of Human Subjects for Teaching and Research. Subjects will be given their written informed consent before participating in the study. Urine samples (50 ml each) will be collected the day before the administration and at 0 to 3h, 3 to 6h, 6 to 9h and 9 to 12h after administration. Plasma and urine fractions will be stored at -80°C until analysis. ;

Study Design

Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02359396
Study type	Interventional
Source	Hong Kong Baptist University
Contact
Status	Completed
Phase	Phase 1
Start date	November 2014
Completion date	August 2015

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT04506801` - The Effect of Probiotics on Functional Constipation in the Elderly	N/A
Completed	`NCT04620161` - A Proof of Concept Study of Pradigastat in Patients With Functional Constipation	Phase 2
Active, not recruiting	`NCT02361749` - Botulinum Toxin Injection Versus Anal Myectomy in Management of Idiopathic Constipation	Phase 4
Completed	`NCT03054805` - The Effect of Probiotics on Constipation, and Intestinal Microflora in Children With Functional Constipation	Phase 4
Not yet recruiting	`NCT01913665` - The Effect of Bifidobacterium Lactis and Inulin on Functional Constipation	N/A
Completed	`NCT01348152` - Effect of TU-100 in Patients With Functional Constipation	Phase 2
Completed	`NCT01622972` - Mode of Action of Moviprep	Phase 4
Completed	`NCT01212146` - Probiotic-enriched Artichoke in Functional Constipation	N/A
Completed	`NCT04231162` - Effect of an 8-week Bifidobacterium Lactis HN019 Supplementation on Functional Constipation	N/A
Not yet recruiting	`NCT03639142` - Dried Plums (Prunes) vs. Polyethylene Glycol 4000 for Treatment of Functional Constipation in Children	Phase 3
Recruiting	`NCT04918329` - Functional Digestive Disorders Observatory
Completed	`NCT02592200` - Effect of Lactobacillus Gasseri DSM 27123 on Functional Constipation in Healthy Women	N/A
Completed	`NCT03707002` - Effect of scFOS on Increase in Stool Frequency in Constipated People	N/A
Recruiting	`NCT06083311` - The Efficacy of a Probiotic for Functional Constipation (FC)	N/A
Completed	`NCT04110145` - Linaclotide Safety and Efficacy in 2 to 5-Year-Old Participants With Functional Constipation	Phase 2
Recruiting	`NCT06196073` - Visceral Osteopathy in Functional Constipation	N/A
Completed	`NCT04026113` - Linaclotide Safety and Efficacy in Pediatric Participants, 6 to 17 Years of Age, With Irritable Bowel Syndrome With Constipation (IBS-C) or Functional Constipation (FC)	Phase 3
Completed	`NCT01847950` - Effects of scFOS on Stool Frequency in People With Functionnal Constipation	N/A
Recruiting	`NCT01274793` - Trial for Quantity-Effect Relationship of Acupuncture With Two-ways Regulation to Treat Functional Enteropathy	Phase 1
Active, not recruiting	`NCT04166058` - Long-term Safety of Linaclotide in Pediatric Participants With FC or IBS-C	Phase 3

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

A Randomized, Open-label, Three-arm Study of MZRW on Tolerability, Exposure and Pharmacokinetics

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms